Related Experiment Video

Updated: May 2, 2026

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa
07:27

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa

Published on: July 12, 2018

4.9K

Kidney Targeting Smart Antibiotic Discovery: Multimechanism Pleuromutilins for Pyelonephritis Therapy

Lei Tian1,2, Taotao Qiang1, Juan Xia3

  • 1College of Bioresources Chemical and Materials Engineering, Shaanxi University of Science & Technology, Xi'an 710021, China.

Journal of Medicinal Chemistry
|January 15, 2025
PubMed

Insights

New antibiotic candidate 8i targets drug-resistant bacteria by disrupting protein synthesis and damaging membranes. This novel organ-targeted approach shows promise for treating systemic infections and pyelonephritis with reduced toxicity.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Microbiology

Background:

  • Multidrug-resistant (MDR) bacteria present a significant global health challenge, necessitating the development of novel antibiotics.
  • Lefamulin, a pleuromutilin, offers a new mechanism but faces limitations in pharmacokinetics and organ toxicity.
  • Modifications to lefamulin are crucial to enhance its therapeutic potential against resistant pathogens.

Purpose of the Study:

  • To design and synthesize novel pleuromutilin derivatives with improved pharmacokinetic properties and targeted organ delivery.
  • To evaluate the efficacy of these derivatives against a range of MDR bacteria, including atypical pathogens.
  • To elucidate the mechanism of action and assess the safety profile of promising candidates.

Main Methods:

  • Chemical modification of lefamulin's C14 side chain through quaternization and incorporation of rigid fragments.
  • In vitro testing of synthesized compounds against MDR bacteria, Mycoplasma, and Chlamydophila.
  • Assessment of organ targeting via organic cation transporters (OCTs) and evaluation of pharmacokinetic properties.
  • In vivo studies to determine efficacy in treating systemic infections and pyelonephritis, and to assess toxicity.

Main Results:

  • Candidate 8i, a quaternized imidazo[4,5-c]pyridine pleuromutilin, exhibited broad-spectrum activity against MDR bacteria at low concentrations.
  • 8i demonstrated targeted delivery to infected kidneys, biofilm disruption, membrane damage, and inhibition of protein synthesis via the 50S ribosomal subunit.
  • The compound showed rapid clearance, suggesting reduced potential for long-term organ toxicity.
  • Short-course daily injections of 8i proved effective for treating systemic infections and pyelonephritis in preclinical models.

Conclusions:

  • Novel quaternized pleuromutilin derivative 8i demonstrates potent activity against MDR bacteria and atypical pathogens.
  • OCT-mediated, organ-targeted delivery represents a promising strategy for enhancing antibiotic efficacy and reducing toxicity.
  • This approach offers a new avenue for developing effective treatments against challenging antibiotic-resistant infections.

More Related Videos

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation07:40

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

Published on: August 30, 2019

10.0K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

1.4K

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

Overview
52.2K
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.1K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.7K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
325
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
117